Shanghai, China October 15, 2018--Shanghai HaiHe Biopharma Co., Ltd. (hereinafter referred to as “HaiHe Biopharma”) and Taiwan Microbio Group (hereinafter referred to as “Microbio”) announced today that the national investigator meeting on the phase III clinical trial of ON101, an innovative drug jointly developed by the both parties, was successfully convened in Shanghai recently. The clinical trial will be conducted under the leadership of Academician Ning Guang of Shanghai Ruijin Hospital.

It is estimated that there are 110 million patients with diabetes in China. The prevalence of diabetic foot ulcer (DFU) in diabetic patients is about 4-10%, and there is a high recurrence rate. Currently the total number of patients with diabetic foot in China is about 7.5 million, however, there is no effective enough treatment. To address such huge unmet clinical need, HaiHe Biopharma and Microbio had worked together on the development of ON101 in China. The product is an ointment made from the extracts of Plectranthus amboinicus/Centella Asiatica. The phase III clinical trial is being carried out smoothly in Taiwan, with results showing that the product has good safety and efficacy. “China has a huge population of diabetic foot patients.. Being a bio-tech company dedicated to the R&D of the innovative drugs, we feel obliged to introduce this product into China and expedite the development. Hopefully it will be marketed as early as possible for the benefit of the Chinese patients. We are glad to see the successful convening of the national investigator meeting on ON101. We would like to extend our sincere thanks to Academician Ning Guang and relevant experts for their great support and wish the clinical trial a complete success,” said Dr. Dong Ruiping, CEO of HaiHe Biopharma. “The launch of the phase III clinical trial marks a significant progress achieved by the ON101 project in mainland China, thanks to the joint efforts rendered by our business partner HaiHe Biopharma. We hope that ON101 will be approved for marketing as early as possible for the benefit of our compatriots who are in urgent need.” said Mr. Lu Kongming, Chairman of MICROBIO GROUP.

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. It also has a research and management team with a global perspective, and is proactively mapping out the international development of innovative drugs. The Company currently has thirteen key drug candidates. As of today, Haihe Biopharma has received 21 IND or clinical trial approvals in four countries and regions. 

MICROBIO, which was founded in 2000, has experienced over a decade of growth and remains dedicated to “novel therapeutics development and human lifestyle improvement”. MICROBIO Group’s approach to innovative and responsible drug development has led to two successful drug approvals by the Taiwanese Food and Drug Administration (TFDA). In addition to drug development, we have expanded into other markets such as top-line medical devices, functional health foods, organic agricultural products, and biotechnology venture capital. We always welcome strategic collaborations with leading research institutions, international pharmaceutical companies, and novel biotechnology platforms, all of which allow us to bridge gaps in medical treatments. It is our mission to fulfill unmet healthcare needs, and transform scientific breakthroughs into clinical research in the hopes of providing new treatment options for patients. Our core values, modesty and innovation, drive us to take initiative, stay competitive, and position us as an influential leader in the global market.